Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Coherus Oncology, Inc.
National Cancer Institute (NCI)
Hoffmann-La Roche
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Institutes of Health Clinical Center (CC)
AbbVie
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
St. Jude Children's Research Hospital
Centre Hospitalier Universitaire de Besancon
Boehringer Ingelheim
National Cancer Institute (NCI)
Hoffmann-La Roche
University of Washington
Hoffmann-La Roche
Big Ten Cancer Research Consortium
Genentech, Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Hoffmann-La Roche
M.D. Anderson Cancer Center
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Hoffmann-La Roche
Charite University, Berlin, Germany
University of Geneva, Switzerland
The Methodist Hospital Research Institute
Federation Francophone de Cancerologie Digestive
Genentech, Inc.
Hoffmann-La Roche
Genentech, Inc.